NEW YORK (GenomeWeb News) – Metabolon has raised $5.3 million from a Series C funding round, the firm said today.

The Research Triangle Park, NC-based metabolomics services company said that it anticipates raising a total of $11 million in the round. It closed the first $5.3 million last week, and it expects to receive the rest of the funding within the next 60 to 90 days.

Metabolon CEO John Ryals said that the funding will enable the firm to launch its diagnostics business with products for prostate cancer and insulin resistance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.